ECT for Bipolar Depression: A Guide for Patients and Families

If you or someone you care about is at the point where ECT is being discussed, that in itself tells you something about the journey that has already been travelled. It means other options have been tried, or that the situation is serious enough to need rapid action. Reaching this point can feel daunting, and finding straightforward, honest information is not always easy.

This article is intended to help. It covers what ECT is, how it is used specifically in bipolar depression (which involves some important differences from unipolar depression), what the research says about risks and outcomes, and what questions it is worth taking to your care team.

What Is ECT and How Is It Used in Bipolar Disorder?

Electroconvulsive therapy (ECT) involves delivering a controlled electrical stimulus to the brain, producing a brief, supervised seizure under general anaesthetic. It always takes place in a clinical setting, with an anaesthetist and a clinical team present. Despite the associations it may carry for many people, ECT is a well-established, often fast-acting, potentially life-saving treatment with a substantial evidence base, and the procedure itself is very different from historical depictions.

In bipolar disorder, ECT tends to be considered when someone is severely depressed and other treatments have been unsuccessful; when depression is accompanied by severe psychosis or catatonia; where rapid symptom relief is a clinical priority due to the level of risk of malnutrition, dehydration, suicide or serious self-harm; or when a person has previously responded well to ECT. Guidelines for ECT use in bipolar depression may differ between countries, for example, the CANMAT 2025 guidance, positions ECT as a second-line option in bipolar depression, particularly where psychotic features are present [Ref 3] whereas [REF 4] guidance takes a more cautious approach requiring failure of multiple treatments or the presentation to be considered life-threatening.

How ECT differs from tDCS

Although ECT and tDCS both use electricity to treat depression, that’s where the similarities end as they are very different types of intervention. ECT uses around 800 milliamperes of electrical current and produces a seizure under anaesthetic, in a hospital setting. Transcranial direct current stimulation (tDCS) is a very different treatment: it uses a tiny current around 400 times weaker (typically 1 to 2 milliamperes), produces no seizure, requires no anaesthetic, and can be used at home whilst going about regular activities. It’s a bit like comparing riding on a rocket ship with a pushbike.

The two also sit at very different points on the care pathway. ECT is a hospital-based intervention for the more acute or treatment-refractory end of the clinical picture. tDCS is a non-invasive option currently under investigation for bipolar depression, though it is not yet licensed for this use. Both are mentioned in this article because both are relevant to the broader question of brain stimulation in bipolar disorder.

The Risk of Mood Switching: What You Need to Know

What is a mood switch?

A mood switch refers to a shift from a depressive state into hypomania or mania during the course of treatment. In the context of ECT, this means that someone receiving treatment for a depressive episode may begin to develop elevated mood, increased energy, reduced need for sleep, or other features of hypomania or mania. This is a recognised risk in bipolar depression and one that clinical teams monitor for throughout a course of ECT.

How common is it?

A retrospective study of 100 bipolar inpatients found that approximately one in four switched to hypomania or mania during a course of ECT, with the risk being higher when more sessions were given without concurrent anti-manic medication cover [Ref 1]. That is a meaningful figure, and it is worth knowing about. It also illustrates why clinical monitoring throughout a course of ECT is so important: teams are looking for exactly this pattern, and treatment can be adjusted if it begins to emerge. A mood switch is often manageable when it is caught early.

Does taking antidepressants increase the risk?

This is useful context for anyone who has previously been prescribed antidepressants for low mood in the context of bipolar disorder. Antidepressant monotherapy, meaning taking an antidepressant without a mood stabiliser, is not recommended in bipolar depression, in part because of the risk this carries of triggering a switch into elevated mood [Ref 2] [Ref 3]. This is one of the reasons medication management in bipolar disorder is more complex than in unipolar depression, and why the involvement of a psychiatrist with experience in bipolar disorder matters so much.

What to Expect Before, During and After ECT

Before treatment

ECT is always preceded by a thorough assessment process. This includes a review of your full medical history, baseline cognitive testing, a physical examination, blood tests, and an anaesthetic review to ensure you are fit for the procedure. You will be asked to give informed consent before any treatment begins, and that consent should feel genuinely voluntary rather than pressured. Nothing happens without proper preparation, and you have the right to ask questions at every stage.

During a course of ECT

A typical course involves 6 to 12 sessions, given two to three times per week. Each session is short. You will be given a general anaesthetic which includes a muscle relaxant to reduce how much your body moves during the procedure, the stimulus will be delivered to induce a short seizure in the brain, and you will come round in a recovery area. The clinical team will assess your response as the course progresses and adjust the plan accordingly.

Recovery and side effects

The most commonly reported side effect of ECT is short-term memory difficulty, which can affect the ability to recall recent events or new information during and after the course of treatment. For most people this improves once treatment ends, but for some it can persist for longer, and in a minority of cases there may be more lasting effects on memory. This is something to discuss honestly with your care team before starting, and it is worth asking specifically what they have observed in their own patient group.

Other reported side effects include headache, muscle aches, nausea, and confusion in the hours immediately after a session. These are generally short-lived.

Questions to Ask Your Care Team

Going into a conversation about ECT with a list of specific questions makes a real difference. Here are some that I think are worth raising:

• What alternatives have been considered, and why is ECT the recommendation at this point?
• What mood-stabilising medication will I be taking alongside ECT, and how will that be managed?
• How will you monitor for signs of hypomania or mania during the course of treatment?
• How many sessions are planned, and how will you assess whether I am responding?
• What should my family and I watch for between sessions, and who should we contact if we are concerned?
• What is your experience of ECT outcomes in patients with bipolar disorder specifically?

A note on second opinions

Seeking a second opinion before starting ECT if you feel unsure about this decision is entirely reasonable, and a good clinician will support you in doing so. Having another psychiatrist review your case is not a sign of distrust; it is a normal part of making an informed decision about a significant intervention.

Emerging Research: Brain Stimulation Options for Bipolar Depression

What does the research say about tDCS?

tDCS has attracted growing research interest as a potential treatment for bipolar depression. A 2022 systematic review found that tDCS was effective for bipolar depression, with depression scores reducing by 18 to 92% across a total of 207 patients in the included studies [Ref 5]. A 2024 meta-analysis found a significant improvement with active tDCS versus sham stimulation in bipolar depression, with an effect size of 1.17 [Ref 6]. An open-label study using the Flow device at home in people with bipolar depression found significantly positive clinical outcomes and good acceptability [Ref 7], and a 2025 publication reported specifically on the effects of home-based tDCS on cognitive functioning in bipolar depression with similarly encouraging results [Ref 8].

While research into tDCS for bipolar depression is promising, devices of this type are not currently licensed for this use. Treatment decisions should always be discussed with a psychiatrist.

What does this mean right now?

The honest position is that whilst the science is encouraging, more research is needed before tDCS can be recommended as a standard treatment for bipolar depression. To increase the evidence base in this important area, the Kings College London research team in collaboration with Bipolar UK, NIHR, and NHS partners are currently undertaking a randomised control trial using the Flow tDCS headset. You can find out more about this study, including information about taking part here.

In the meantime, if you are interested in understanding more about tDCS, it is worth a discussion with your psychiatrist. They will be able to help you understand more in the context of your individual circumstances, and to plan any treatment changes within a properly supervised framework.

Key Takeaways

• ECT is a well-established treatment for depression, including bipolar depression, and is typically considered when medication has not been effective, when psychosis is present, or when rapid symptom relief is needed. Current guidelines position it as a second-line or emergency/treatment-refractory option depending on where you live [Ref 3].
• NICE guidance takes a more cautious approach requiring failure of multiple treatments or the presentation to be considered life-threatening [Ref 4].
• Mood switching is a recognised risk in bipolar depression during ECT. Research suggests approximately one in four patients may experience a shift to hypomania or mania [Ref 1]. This is monitored throughout treatment and can be managed.
• Antidepressant monotherapy is not recommended in bipolar depression because of mood switch risk. Medication management in bipolar disorder is more complex than in unipolar depression, and mood stabilisers are a central part of the picture.
• The most significant side effect of ECT is short-term memory difficulty. For most people this improves after treatment, but it is important to discuss the evidence on memory effects honestly with your care team before starting.
• Going into conversations with your care team with specific questions makes a real difference. Seeking a second opinion before starting ECT if there are reservations is reasonable and supported.
• Research into tDCS for bipolar depression is growing and shows promising results [Ref 4] [Ref 5], but devices of this type are not yet licensed for bipolar depression. Anyone interested should raise it with their psychiatrist.

Moving Forward

ECT can feel like a significant step, and it is natural to want to understand it thoroughly before agreeing to proceed. It is crucial that you feel able to have an open, honest conversation with your care team, to ask questions, to request a second opinion if you want one, and to make a decision that feels right for you given the full picture. Take what you have read here and use it to inform those conversations.

Flow is a medical device approved for the treatment of depression. Approved treatments for depression should be discussed with and supervised by your doctor.

References

Ref 1: Bost-Baxter et al. (Longdom Publishing). https://www.longdom.org/open-access/ect-in-bipolar-disorder-incidence-of-switch-from-depression-to-hypomania-or-mania-26585.html

Ref 2: CANMAT and ISBD Guidelines 2023 Update (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC11058959/

Ref 3: CANMAT Clinical Practice Guidelines 2025 (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC12900052/

Ref 4: National Institute for Health and Care Excellence. (2022). Depression in adults: treatment and management: NICE guideline NG222.
https://www.nice.org.uk/guidance/ng222/chapter/recommendations#further-line-treatment

Ref 5: Sciortino et al. 2022 (ScienceDirect). https://www.sciencedirect.com/science/article/abs/pii/S0278584622001646

Ref 6: Hsu et al. 2024 (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC11336151/

Ref 7: Woodham et al. (Int J Bipolar Disorders, 2024). https://link.springer.com/article/10.1186/s40345-024-00352-9

Ref 8: Rezaei et al. 2025 (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914700/

Dr Hannah Nearney MBChB, MRCPsych, MSc, PGDip(CAT) is a Consultant Psychiatrist specialising in general adult psychiatry, including adult ADHD, autism, and women's mental health. She is UK Medical Director at Flow Neuroscience and a founding partner at Anchor Psychiatry Group in East Anglia. She is a Fellow on the NHS Innovation Accelerator program (2026 cohort) which provides support to scale evidenced-based innovations like Flow tDCS in the NHS to enhance patient outcomes and service delivery. Follow her on Instagram: @psychiatristhannah